Prothena authorizes up to $100M share repurchase plan through Dec 31, 2026

PROTHENA CORP PUBLIC LTD CO

Board authorized repurchase of up to $100M of ordinary shares; plan expires Dec 31, 2026.
Company had $308.4M cash and no debt as of Dec 31, 2025.
Guidance (excluding buyback) expects ~$255M cash at year-end 2026.
Potential to earn up to $105M in clinical milestone payments from partners in 2026.
Repurchases are discretionary; no obligation to buy any shares.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.